Prescient Therapeutics (ASX:PTX) manufactures new range of binders for CAR-T cancer therapy
Prescient Therapeutics (PTX) has slipped on the ASX today despite announcing some key developments for...
Prescient Therapeutics (PTX) has slipped on the ASX today despite announcing some key developments for...
Prescient Therapeutics (PTX) has announced a new research program with the Peter MacCallum Cancer Centre...
Prescient Therapeutics (PTX) will progress to the next dose level of its Phase 1b clinical...
Prescient Therapeutics (PTX) outperformed its health sector peers on the ASX today after releasing its...
Two of Prescient Therapeutics' (PTX) assets have been handpicked for a COVID-19 antiviral testing program....
Anti-cancer biotech company Prescient Therapeutics (PTX) has received two key licences to build a new...
Anti-cancer biotech company Prescient Therapeutics (PTX) has received two key licences to build a new...
Prescient Therapeutics (PTX) shares rose 60 per cent this morning after expanding its Phase 1b...
Prescient Therapeutics has entered a collaboration with Carina Biotech to develop new targeted cell therapies...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.